Besides their phenotypic characteristics, the functionality and specificity of all five CliniMACS Prodigy-manufactured RevCAR and Dual-RevCAR T cell products were confirmed by their demonstrated strong cytotoxic activity (Figure 6 and Figure 7) and cytokine secretion (Supplementary Figures S2 and S3) only upon cross-linkage with tumor cells via RevTM PSMA-7B6 either alone (RevCAR T cells) or in combination with RevTM PSCA-5B9 (Dual-RevCAR T cells). The gene discussed is FOLH1; the disease is neoplasm.